GEVA
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
GEVA
Delisted
GEVA was delisted on the 22nd of June, 2015.
126 hedge funds and large institutions have $3.37B invested in SYNAGEVA BIOPHARMA CORP COM STK (DE) in 2014 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 46 increasing their positions, 37 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
126
Holders Change
+6
Holders Change %
+5%
% of All Funds
3.36%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
23
Increased
46
Reduced
37
Closed
15
Calls
$9.78M
Puts
$12.9M
Net Calls
-$3.12M
Net Calls Change
+$627K
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$65.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$44.9M |
| 3 |
JPMorgan Chase & Co
New York
|
+$10.5M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$8.26M |
| 5 |
Allianz Asset Management
Munich,
Germany
|
+$7.47M |
Top Sellers
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$22.1M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$13.3M |
| 3 |
FAM
Fred Alger Management
New York
|
-$9.77M |
| 4 |
CWAM
Columbia Wanger Asset Management
Chicago,
Illinois
|
-$7.42M |
| 5 |
AC
Ascend Capital
Orinda,
California
|
-$5.85M |
